Author: Tsuzuki, S.; Hayakawa, K.; Matsunaga, N.; Terada, M.; Suzuki, S.; Ohtsu, H.; Asai, Y.; Kitajima, K.; Saito, S.; Uemura, Y.; Shibata, T.; Kondo, M.; Izumi, K.; Hojo, M.; Mizoue, T.; Yokota, K.; Nakamura-Uchiyama, F.; Saito, F.; Sugiura, W.; Ohmagari, N.
Title: Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan Cord-id: ro7fmgt9 Document date: 2021_3_10
ID: ro7fmgt9
Snippet: Objectives Results from several randomised controlled trials comparing the efficacy of remdesivir with placebo have been reported. Data on the efficacy of remdesivir in Asian populations are limited, and conflicting results have been reported. The aim of the present study is to examine whether remdesivir is effective for the treatment of COVID-19 or not. Methods We evaluated the efficacy of remdesivir from data acquired from the COVID-19 Registry Japan, a nationwide registry of Japanese patients
Document: Objectives Results from several randomised controlled trials comparing the efficacy of remdesivir with placebo have been reported. Data on the efficacy of remdesivir in Asian populations are limited, and conflicting results have been reported. The aim of the present study is to examine whether remdesivir is effective for the treatment of COVID-19 or not. Methods We evaluated the efficacy of remdesivir from data acquired from the COVID-19 Registry Japan, a nationwide registry of Japanese patients hospitalised with COVID-19, using five-to-one propensity score (PS) matching. Primary outcomes were overall risk of fatality, risk of invasive mechanical ventilation or extracorporeal membrane oxygenation (IMV/ECMO) and length of stay (LoS) in healthcare facilities. Results In total, 1907 of 15,225 patients met our inclusion criteria. After PS matching, 74 patients were assigned to the remdesivir case group and 195 patients to the non-remdesivir control group. In a PS-matched cohort, fatality risk (12.2% vs 13.3%; P = 1.0); risk of IMV/ECMO (5.4% vs 4.6%; P = 0.757); length of intensive care unit stay (6 vs 6 days; P = 0.473) and length of IMV (13 vs 5 days; P = 0.509) were not different between the case and control groups. LoS in the case group was longer than in the control group (14 vs 11 days; P < 0.001). Conclusions This study suggested that remdesivir may have no positive effect on clinical outcomes and reductions in invasive/non-invasive respiratory support for patients with COVID-19 in Japan.
Search related documents:
Co phrase search for related documents- acid amplification and administration remdesivir: 1
- acid amplification and admission day: 1, 2
- acid amplification and logistic regression: 1, 2, 3, 4
- additional study and administration duration: 1
- additional study and admission day: 1
- additional study and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- additional study and long hospital care: 1
- administration duration and liver enzyme: 1
- administration duration and logistic regression: 1, 2, 3, 4
- administration remdesivir and logistic regression: 1
- administration remdesivir and logistic regression model: 1
- admission condition and logistic regression: 1, 2, 3, 4
- admission condition and logistic regression model: 1, 2, 3
- admission day and liver enzyme: 1
- admission day and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission day and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- admission symptom onset and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- admission symptom onset and logistic regression model: 1
- liver enzyme and logistic regression model: 1
Co phrase search for related documents, hyperlinks ordered by date